Search research articles
Contact Us
Filters
Showing results (131-140 of 191) with videos related to
Page
of 20
Sort By:
The Journal of Infection
|
October 20, 2019
Consensus recommendations for resistance testing in the management of chronic hepatitis C virus infection: Public Health England HCV Resistance Group
Daniel Bradshaw, Jean L Mbisa, Anna Maria Geretti, et al.
Travel Medicine and Infectious Disease
|
September 7, 2013
The prevalence of hepatitis C virus among people of South Asian origin in Glasgow - results from a community based survey and laboratory surveillance
Maureen C O'Leary, Mohammed Sarwar, Sharon J Hutchinson, et al.
Plos One
|
April 11, 2020
Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis B
Patrick Marcellin, Qing Xie, Seung Woon Paik, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
August 25, 2016
Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials
Jason Grebely, Gregory J Dore, Stefan Zeuzem, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
October 17, 2014
Low-density lipoprotein and other predictors of response with telaprevir-based therapy in treatment-experienced HCV genotype 1 patients: REALIZE study
Thomas Berg, Pietro Andreone, Stanislas Pol, et al.
Open Forum Infectious Diseases
|
November 16, 2018
Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials
Jason Grebely, Massimo Puoti, Heiner Wedemeyer, et al.
Hepatology (Baltimore, Md.)
|
October 19, 2011
The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C
Stefan Zeuzem, Peter Buggisch, Kosh Agarwal, et al.
Journal of Viral Hepatitis
|
February 28, 2026
The Impact of Hepatitis C and Socio-Demographic Variables on Health-Related Quality of Life in Pakistan: Cross-Sectional Study
Siwaporn Niyomsri, Aaron G Lim, Ambreen Arif, et al.
Hepatology (Baltimore, Md.)
|
January 3, 2014
Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial
Zobair Younossi, Francesco Negro, Lawrence Serfaty, et al.
Journal of Hepatology
|
August 10, 2017
Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries
Ana da Silva Filipe, Vattipally Sreenu, Joseph Hughes, et al.
Page
of 20
Search research articles
Search
Showing results (131-140 of 191) with videos related to
Sort By:
Page
of 20
The Journal of Infection
|
October 20, 2019
Consensus recommendations for resistance testing in the management of chronic hepatitis C virus infection: Public Health England HCV Resistance Group
Daniel Bradshaw, Jean L Mbisa, Anna Maria Geretti, et al.
Travel Medicine and Infectious Disease
|
September 7, 2013
The prevalence of hepatitis C virus among people of South Asian origin in Glasgow - results from a community based survey and laboratory surveillance
Maureen C O'Leary, Mohammed Sarwar, Sharon J Hutchinson, et al.
Plos One
|
April 11, 2020
Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis B
Patrick Marcellin, Qing Xie, Seung Woon Paik, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
August 25, 2016
Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials
Jason Grebely, Gregory J Dore, Stefan Zeuzem, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
October 17, 2014
Low-density lipoprotein and other predictors of response with telaprevir-based therapy in treatment-experienced HCV genotype 1 patients: REALIZE study
Thomas Berg, Pietro Andreone, Stanislas Pol, et al.
Open Forum Infectious Diseases
|
November 16, 2018
Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials
Jason Grebely, Massimo Puoti, Heiner Wedemeyer, et al.
Hepatology (Baltimore, Md.)
|
October 19, 2011
The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C
Stefan Zeuzem, Peter Buggisch, Kosh Agarwal, et al.
Journal of Viral Hepatitis
|
February 28, 2026
The Impact of Hepatitis C and Socio-Demographic Variables on Health-Related Quality of Life in Pakistan: Cross-Sectional Study
Siwaporn Niyomsri, Aaron G Lim, Ambreen Arif, et al.
Hepatology (Baltimore, Md.)
|
January 3, 2014
Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial
Zobair Younossi, Francesco Negro, Lawrence Serfaty, et al.
Journal of Hepatology
|
August 10, 2017
Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries
Ana da Silva Filipe, Vattipally Sreenu, Joseph Hughes, et al.
Page
of 20